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Abstract
Atrial ﬁbrillation (a-ﬁb) is one of the most frequently encountered and studied arrhythmias in medicine. The presence
of A-ﬁb in the post-operative period of coronary artery bypass graft (CABG) surgery is of particular concern for clinicians
as this presents risks of post-operative stroke, hospital readmission, or anticoagulation dilemmas depending on the
patient's comorbidities. In this case study, we present 5 patients who were treated with dronedarone prior to undergoing
open heart procedures. We subsequently followed each patients clinical course paying close attention for any evidence
of post-operative a-ﬁb.
Keywords: Atrial ﬁbrillation, Dronedarone, Coronary artery bypass graft, Postoperative arrhythmia

1. Introduction
trial ﬁbrillation (a-ﬁb) is the most common
arrhythmic complication from coronary artery bypass graft (CABG) surgery accounting for
approximately 15e40% of all complications of this
surgery.1 In aortic valve replacement surgeries, this
number is larger ranging from 37 to 50% incidence
in the early post-operative period.2 Typically, the
peak incidence for post-operative atrial ﬁbrillation
(POAF) is on postoperative day 2; making a-ﬁb
prophylaxis an important part of patients perioperative clinical care.2 Current management in the
perioperative period of CABG entails pre- and postoperative treatment with amiodarone to prophylaxis against atrial ﬁbrillation.3 In a 2006 metaanalysis, this was demonstrated to both reduce
length of stay and reduce postoperative stroke
incidence.2 The pathophysiology of POAF is
multifactorial and somewhat theoretical including

A

inﬂammation around the atrium with possible
remodeling of the atrial electrical conduction system.4 Overall, this topic is of importance as atrial
ﬁbrillation confers a long-term mortality risk, impacts in-hospital stroke burden, and can signiﬁcantly change a patient's quality of life. Moreover, it
correlates with an increased utilization of hospital
resources and subsequent increase in cost for the
health care system.5 Amiodarone is a commonly
prescribed medication but it does come with the
risk of several side effects which prevents its usage
across all patients for atrial ﬁbrillation prevention
post-cardiac surgery.3,6 While the efﬁcaciousness of
amiodarone has been demonstrated in multiple
trials such as the ARCH trial and PAPABEAR trial,
additional anti-arrhythmic medications are available and require further investigation. One medication that is available as a potentially safer
alternative is dronedarone, which was studied in
several trials including the PALLAS trial, ATHENA
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trial, and DIONYSOS trial for POAF prophylaxis.7
The primary intent of this case series is to extrapolate from the literature regarding the use and
pharmacology of dronedarone while analyzing its
effect in prevention of atrial ﬁbrillation in the patients we studied who underwent an open-heart
surgical intervention.

2. Methods
This observational case series was conducted
among patients admitted to our hospital who after
undergoing cardiac interventions, were found to
have indications for open heart surgery, primarily
coronary artery bypass grafting or valve repair. A
retrospective chart review was performed on 6 patients who were deemed to have clinical indications
for open heart surgery and met inclusion criteria for
dronedarone use. The inclusion criteria for patients
in this study were no previous history of atrial
ﬁbrillation (permanent or paroxysmal) or use of
anti-arrhythmic drugs, no history of heart failure,
and consent for the clinically indicated open heart
surgical procedure. One patient was excluded as
they did not undergo open heart surgery. Each
patient was prescribed dronedarone 400 milligram
(mg) per oral (po) twice daily (bid) from the cardiologist upon consenting for the open heart surgical
intervention. Patients were subsequently taken for

the surgical procedure and telemetry data and
electrocardiograms (EKG) in the postoperative
period were reviewed for evidence of atrial
ﬁbrillation.
2.1. Patient case 1
72 year old male with a history of type 2 diabetes
mellitus (T2DM), coronary artery disease (CAD)
status post percutaneous coronary intervention
(PCI) with 3 stents, hypertension (HTN), hyperlipidemia (HLD) presented with complaints of 2 week
history of chest pain worse with exertion, associated
with shortness of breath and diaphoresis. His point
of care (POC) troponin was 0.68 ng/mL and lab
troponin was 1.19 ng/mL. Admission EKG demonstrated normal sinus rhythm (NSR) with left bundle
branch block (Fig. 1a). He was treated as non-stelevation myocardial infarction (NSTEMI) and taken
for left heart catheterization (LHC) on hospital day
2. LHC revealed triple vessel disease and the patient
was referred to cardiothoracic surgery for CABG
and dronedarone 400 mg po bid was started. CABG
was performed on hospital day 5. EKG on hospital
day 7 demonstrated atrial ﬁbrillation with rapid
ventricular response (Fig. 1b). The patient subsequently underwent transesophageal echocardiogram guided cardioversion on hospital day 7. This
was shown to be successful.

Fig. 1. a Pre - Operative EKG for patient 1: Sinus rhythm, Left axis deviation, Left bundle branch block. Qtc 428 ms (ms), Ventricular rate 74 beats per
minute (BPM), QRS 140 ms. Post - Operative EKG for patient 1 notable for Atrial ﬁbrillation with rapid ventricular response, QTc 488 ms, Ventricular rate 151 BPM, QRS 126 ms.
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2.2. Patient case 2

2.3. Patient case 3

77-year-old male with a past medical history of
CAD status post stent to left anterior descending
artery (LAD), HTN, sick sinus syndrome status post
pacemaker, T2DM who presented for elective left
heart catheterization. EKG on admission demonstrated sinus bradycardia, right bundle branch, and
t wave abnormalities (Fig. 2a). On admission, his
POC troponin was 0.01 ng/mL. Left heart catheterization demonstrated left main artery disease and in
stent restenosis of the stent in the LAD and patient
was scheduled for CABG. Two days prior to the
procedure, the patient was started on dronedarone
400 mg po bid. On pump CABG was performed
with grafts created from left internal mammary artery (LIMA) to (LAD) and saphenous venous graft
(SVG) to ﬁrst obtuse marginal (OM1) artery. There
were no intraoperative or postoperative complications. Post-operative ejection fraction (EF) was 55%.
Postoperative EKG demonstrated NSR and an
incomplete right bundle branch block (Fig. 2b). The
patient was discharged on dronedarone on postoperative day (POD) 4. The patient remained in
normal sinus rhythm throughout his postoperative
hospital course.

51-year-old male with past medical history of
HTN, HLD, meniere's disease and T2DM who
presented with 8/10 chest pain (0 being no pain, 10
being the worst pain of their life) associated with
shoulder pain and diaphoresis. EKG demonstrated
NSR, right bundle branch block pattern (Fig. 3a).
Troponin was 0.245 ng/mL on admission. Patient
was diagnosed with NSTEMI and cardiology
was consulted for cardiac catheterization where it
was discovered the patient had 90% occlusion of
the left main artery, 90% occlusion of the ostial
branch of the LAD, and 90% occlusion of the
left circumﬂex. Echocardiogram demonstrated
ejection fraction of 55%. Patient was subsequently
referred to cardiothoracic surgery for CABG and
was started on dronedarone 400 mg bid on
hospital day 1. On pump double vessel CABG
was completed on hospital day 3: LIMA to LAD
and SVG to OM1. Post-operative course was
uneventful. Dronedarone was resumed postoperatively until discharge on hospital day 8. EKG
from hospital day 6 demonstrated: NSR, with right
bundle branch pattern (Fig. 3b). He was discharged
uneventfully.

Fig. 2. a Pre - Operative EKG for patient 2: Atrial paced rhythm, Right bundle branch block, QTc 468, Ventricular rate 60 BPM, QRS 138 ms. Post Operative EKG for patient 2 notable for Normal sinus rhythm, incomplete Right bundle branch block, QTc 482 ms, Ventricular rate 68 BPM, QRS
118 ms.
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Fig. 3. a Pre - Operative EKG for patient 3: Normal sinus rhythm, Right bundle branch block, QTc 462 ms, Ventricular rate 82 BPM, QRS 132 ms.
Post- Operative EKG for patient 3 notable for Normal sinus rhythm, RSR0 suggestive of right bundle branch pattern, QTc 520 ms, Ventricular rate 96
BPM, QRS 118 ms.

2.4. Patient case 4
72-year-old male with past medical history of severe multi-vessel CAD, carotid artery disease, HTN,
T2DM, HLD, chronic kidney disease (CKD) Stage 3
presented to our facility with band like substernal
chest pain that radiated to the jaw which was
relieved with nitroglycerin. Admission EKG
demonstrated NSR (Fig. 4a). He underwent left
heart catheterization on the day of admission and
found to have multi vessel disease with in-stent restenosis. Patient was medically managed with heparin drip, antihypertensive medications as well as
dronedarone 400 mg po bid which was started 2
days prior to CABG. The patient received quadruple
bypass on hospital day 3: LIMA to LAD, SVG to
OM1, SVG to proximal descending artery (PDA),
SVG to 1st diagonal. Post-operative EF was 40e45%.
Post-Operative EKG showed sinus rhythm with 1st
degree block (Fig. 4b). Patient, however, did not
tolerate dronedarone, citing gastrointestinal side
effects. He was switched to amiodarone and discharged uneventfully on hospital day 8.
2.5. Patient case 5
66 year old male with past medical history of hypothyroidism and lymphedema presented for
shortness of breath and worsening lower extremity

peripheral edema. EKG on hospital admission
demonstrated NSR and left ventricular hypertrophy
(Fig. 5a). Echocardiogram on hospital day 1
demonstrated vegetation on the aortic valve (AV)
but had poor acoustic quality so transesophageal
echo was completed on hospital day 3; this
demonstrated EF 55%, irregular solid mobile vegetation on non-coronary cusp of AV, and severe
regurgitation, valve area of 1.67 cm2. Cardiac catheterization was completed which demonstrated no
severe obstructive CAD however conﬁrmed severe
aortic valve regurgitation. He was deemed a surgical
candidate for aortic valve replacement. Patient was
started on dronedarone 400 mg po bid on day 5.
Open heart surgery for valve repair took place on
day 5 with placement of a 23 mm prosthetic tissue
valve. Recovery from cardiac surgery was uneventful. Post-operative EKG showed sinus tachycardia
(Fig. 5b). The patient's hospital course, however, was
complicated with heparin induced thrombocytopenia and bacteremia resulting from the endocarditis. Dronedarone was continued until
discharge on day 34. Sinus rhythm was maintained
throughout this patient's hospital course.

3. Discussion
The primary goal of this case study is to illustrate
the potential utility of perioperative dronedarone in
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Fig. 4. a Pre - Operative EKG for patient 4: Normal sinus rhythm, QTc 428 ms, Ventricular rate 71 BPM, QRS 102 ms. Post - Operative EKG for
patient 4 notable for: Sinus rhythm with 1st degree AV block, QTc 442 ms, Ventricular rate 63 BPM, QRS 100 ms.

the prevention of new onset atrial ﬁbrillation after
open heart surgery in the hospital setting. The
literature has proven that new onset atrial ﬁbrillation after CABG procedures is an independent
predictor of long-term risk for stroke and mortality.8
Thus, providing an effective modality for atrial

ﬁbrillation prophylaxis is an important consideration for these patients, while limiting potential side
effects and re-hospitalizations.
Amiodarone is a commonly utilized antiarrhythmic for atrial ﬁbrillation prophylaxis. In the
ARCH TRIAL, it was demonstrated that amiodarone

Fig. 5. a Pre - Operative EKG for patient 5: Normal sinus rhythm, Left ventricular hypertrophy, QTc 505 ms, Ventricular rate 83 BPM, QRS 116 ms.
Post - Operative EKG for patient 5 notable for Sinus tachycardia, QTc 510 ms, Ventricular rate 102 BPM, QRS 106 ms.
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reduced postoperative atrial ﬁbrillation from 47% in
the placebo arm to 35% in the treatment arm.6 It's
use has been widespread in the prophylactic treatment of atrial ﬁbrillation in both CABG procedures
and valvular interventions. However, one of the
large constraints with amiodarone is the concern of
numerous side effects. These include: QTc interval
prolongation, hypotension, bradycardia, pulmonary
toxicity, hepatotoxicity, and thyroid derangements.7
Dronedarone, a benzofuran derivative comparable to amiodarone, offers a viable alternative. The
designers of the medication sought to improve
amiodarone by creating a de-iodinated variant with
the hopes of reducing the toxicity of the medication.
Subsequently, dronedarone is noted to have
improved pharmacokinetics with a shorter half-life
and reduced accumulation in tissues. These attributes lead to a lower adverse effect proﬁle and
effective maintenance of sinus rhythm in patients
with paroxysmal atrial ﬁbrillation.9 While many
antiarrhythmic medications including sotalol and
dofetilide often require hospitalization to monitor
QTc and development of Torsades de Pointes, dronedarone can safely be started outpatient as the proarrhythmic risks are relatively low. Moreover, patient populations with coronary artery disease could
be started on dronedarone as it was found to be safe
and effective in the ATHENA trial. Given the
improved side effect proﬁle when compared to
amiodarone and our intention to use as a prophylactic agent for atrial ﬁbrillation, we think that dronedarone is a safer alternative with a shorter halflife as to prevent complications and re-hospitalization for our patients who underwent open heart
surgical interventions.
In the PALLAS study, dronedarone was used for
patients with known permanent atrial ﬁbrillation for
at least 6 months prior to being enrolled and was
stopped early due observance of primary endpoints
including stroke, myocardial infarction or death from
cardiovascular causes.10 However, our case series
assessed dronedarone use in patient with no known
history of atrial ﬁbrillation in the past, permanent or
paroxysmal. We used a short course of dronederaone
(2e3 days pre-operative and 2e3 days post operative
from open heart surgical intervention) in an effort to
reduce the known complications and associated
mortality from post operative atrial ﬁbrillation. The
DIONYSOS study was a head to head comparison of
dronederarone vs amiodarone that also had an inclusion criteria of known history of atrial ﬁbrillation
and assessed efﬁcacy of each medication with a primary end point of atrial ﬁbrillation recurrence.9 Again,
our case study included a sample of patients without
history of atrial ﬁbrillation and our objective was to

observe dronedarone use for prevention of new onset
atrial ﬁbrillation among those who underwent open
heart surgical intervention.
The aforementioned ATHENA study, a double
blinded prospective clinical trial, assessed dronedarone 400 mg po bid in patients with paroxysmal
or persistent atrial ﬁbrillation or atrial ﬂutter.
Compared to standard therapy, dronedarone
demonstrated relative risk reduction in ﬁrst hospitalization of 24%. Dronedarone reduced all-cause
mortality by 16%, cardiovascular related mortality
by 29%, stroke mortality by 26%, and overall length
of stay by 1.26 days/patient/year.11 Next, the Euridis
and the Adonis trials studied by Singh et al. evaluated the use of dronedarone in atrial ﬁbrillation and
atrial ﬂutter.12 It was found that dronedarone
signiﬁcantly reduced the risk of atrial ﬁbrillation
recurrence after cardioversion compared to placebo.
The Euridis trial demonstrated a ﬁrst recurrence of
atrial ﬁbrillation reduction of 22% and the EURIDIS
demonstrated at 27.5% reduction. Post procedural
atrial ﬁbrillation prophylaxis data, however, is
limited. Speciﬁcally, on pump/off pump CABG as
well as valvular procedures.
In this small observational case series, we sought
to demonstrate dronedarone as being an effective
agent in the prevention of post-cardiac surgery new
onset atrial ﬁbrillation. Three out of the ﬁve cases in
which dronedarone was utilized demonstrated no
atrial ﬁbrillation after postoperative follow-up in the
inpatient setting. Patient case 4 demonstrated
intolerance to the medication citing gastrointestinal
side effects which is fairly common for this medication. Thus, its ability to maintain sinus rhythm in
that patient was unable to be truly characterized. As
mentioned before, typically the highest incidence of
arrhythmia is on day 2 post operatively but atrial
ﬁbrillation incidence typically remains high in the
acute postoperative period. We sought to demonstrate the potential utility of dronedarone in hospital
for the perioperative period for atrial ﬁbrillation
prophylaxis for multiple cardiac surgical indications
such as CABG, surgical aortic valve repair, etc.
Of course, like any medication, dronedarone is not
without its side effects. Most commonly these patients
will experience diarrhea, nausea (commonly grouped
as gastrointestinal intolerance), bradycardia, or cutaneous rash. Most commonly patients, such as the one
in case 4, will not tolerate dronedarone due to
gastrointestinal side effects. This was also observed in
the DAFNE trial. Prior to use, absolute contraindications to the medication must be considered. Dronedarone is contraindicated in class II/III NYHA heart
failure especially in those with recent decompensation. Another absolute contraindication are patients

with chronic atrial ﬁbrillation. Thus, for the purposes
of this study, patients with prior history of atrial
ﬁbrillation were excluded from the study. Other contraindications clinicians should be cognizant of are
bradycardia especially those with sick sinus syndrome
or heart block, a QTc of 500 milliseconds, patients with
severe hepatic impairment, pregnant women, and
patients on medications such as antifungal or
macrolides.

4. Conclusion
Dronedarone offers a potentially viable solution
for atrial ﬁbrillation prophylaxis post-CABG and
post-valvular intervention. Given the trial data surrounding its use and the favorable side effect proﬁle
in comparison to amiodarone, we hope to shed light
on its potential application for prophylaxis against
postoperative a-ﬁb. Our study demonstrated effective maintenance of normal sinus rhythm in the
immediate postoperative period following open
heart surgical intervention. However, more trial
data is needed for the indication of atrial ﬁbrillation
prophylaxis in the hospital and likely those needing
longer follow up periods.
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